Mexican health regulator COFEPRIS approves the emergency use of Eli Lilly and Co's injectable combination of bamlanivimab and etesevimab to treat mild to moderate COVID-19 cases in people over the age of 12 years who weigh at least 40 kg (88 lb). (Reuters) COVID-19 pandemic in Mexico, COVID-19 drug developmentCOVID-19 pandemic in North AmericaCOVID-19 pandemic link embed save